Biotech trials
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.British Biotech has won regulatory approval to continue two key drug trials. The go-ahead came as it emerged that Dr Andrew Millar is to start his unfair dismissal case against the company at an industrial tribunal next week.
Dr Millar, British Biotech former head of clinical research, was sacked in April after expressing his doubts on the company's anti-pancreatitis drug Zacutex and Marismastat, a cancer treatment, to a British Biotech shareholder.
The company criticised Dr Millar for lifting the secrecy on two trials of Zacutex and Marimastat - a procedure known as "unblinding" - which could have invalidated the trials.
However, British Biotech, whose shares have fallen 85 per cent since the Millar affair broke, said it was now "satisfied that there are no safety issues which would require these clinical trials to be stopped".
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments